Which weight loss drug is more effective?

A 72-week long study of Zepbound and Wegovy found a clear winner

- Bloomberg

Eli Lilly & Co.'s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S's Wegovy in the first head-to-head study (titled SURMOUNT-5 and conducted on 751 randomized participants), of the rival medicines. Zepbound won on all measures of effectiveness in a trial presented Monday at an obesity conference, spurring an average of 47% more weight loss over 72 weeks.